STOCK TITAN

Delcath Systems to Host Third Quarter 2023 Results Call

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary
Delcath Systems, Inc. (Nasdaq: DCTH) will host a conference call on November 13, 2023, at 4:30 PM Eastern Time to discuss results for its third quarter ended September 30, 2023. Participants can dial in or access the webcast to join the call. Replay of the conference will be available until November 20, 2023.
Positive
  • None.
Negative
  • None.

NEW YORK, Nov. 6, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on November 13, 2023, at 4:30 PM Eastern Time to discuss results for its third quarter ended September 30, 2023.  

Conference Call Information

To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call.

Event Date: Monday, November 13, 2023
Time: 4:30 PM Eastern Time
Participant Numbers: Toll Free: 1-833-630-1960
International: 1-412-317-1841
Webcast: https://app.webinar.net/w2e6oOR1rPL

CONFERENCE REPLAY

US Toll Free:

1-877-344-7529

International Toll:

1-412-317-0088

Replay Access Code:

6614259

End Date:

November 20, 2023               

About Delcath Systems, Inc.

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company's proprietary products, HEPZATO KIT (melphalan for Injection/Hepatic Delivery System), approved for use in the United States by FDA, and CHEMOSAT Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), designated under the medical device regulation for use in Europe and the United Kingdom, are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. For more information regarding HEPZATO KIT and its use, including Important Safety Information and Boxed Warning, please visit HEPZATOKIT.com. For more information regarding CHEMOSAT and its use, please visit Chemosat.com.

Investor Relations Contact:

Ben Shamsian
Lytham Partners
646-829-9701
shamsian@lythampartners.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/delcath-systems-to-host-third-quarter-2023-results-call-301979153.html

SOURCE Delcath Systems, Inc.

FAQ

When is Delcath Systems' conference call?

Delcath Systems' conference call is scheduled for November 13, 2023, at 4:30 PM Eastern Time.

What will be discussed during the conference call?

The conference call will discuss the results for Delcath Systems' third quarter ended September 30, 2023.

How can I participate in the conference call?

To participate, dial the provided participant numbers approximately 5 to 10 minutes before the beginning of the call.

What are the participant numbers for the conference call?

The Toll Free participant number is 1-833-630-1960, and the International participant number is 1-412-317-1841.

Can I access the conference call online?

Yes, the conference call can be accessed through the provided webcast link: https://app.webinar.net/w2e6oOR1rPL.

How long will the conference call be available for replay?

The replay of the conference call will be available until November 20, 2023.

What are the replay access details?

For replay, dial US Toll Free: 1-877-344-7529 or International Toll: 1-412-317-0088. The Replay Access Code is 6614259.

Delcath Systems Inc

NASDAQ:DCTH

DCTH Rankings

DCTH Latest News

DCTH Stock Data

138.39M
21.10M
3.21%
27.87%
3.68%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
QUEENSBURY

About DCTH

delcath systems, inc. (nasdaq- dcth) is a specialty pharmaceutical and medical device company focused on the treatment of primary and metastatic liver cancers. our proprietary product---melphalan hydrochloride for injection for use with the delcath hepatic delivery system (melphalan/hds)---is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure. delcath is in late-stage clinical development in the united states with initial commercial activities in europe, where the melphalan/hds is marketed as a ce marked device under the trade name delcath hepatic chemosat® delivery system for melphalan (chemosat). our commercial strategy for chemosat is to steadily grow clinical adoption in major european markets and utilize physician experience to support appeals for reimbursement. since launch over 250 chemosat treatments have been performed at over 20 leading european cancer centers. in 2016, we launched our focus pivotal study in hepatic dominant ocular